Drug Discovery and Chemical Biology of Cancer Epigenetics

Cell Chemical Biology

Volumn 24, Issue 9, 2017, Pages 1120-1147

  Ribich, Scott ^a   Harvey, Darren ^a   Copeland, Robert A ^a  

^a EPIZYME INC   (United States)

Author keywords

cancer; chromatin; epigenetics

Indexed keywords

CANCER GENETICS; CHROMATIN; CITRULLINATION; DRUG DEVELOPMENT; EPIGENETICS; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN METHYLATION; PROTEIN MODIFICATION; REVIEW; ACETYLATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; METABOLISM; METHYLATION; NEOPLASM; PATHOLOGY;

DNA (CYTOSINE 5) METHYLTRANSFERASE; ENZYME INHIBITOR; ESCRT PROTEIN; HISTONE;

ACETYLATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASES; DRUG DISCOVERY; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONES; HUMANS; METHYLATION; NEOPLASMS;

EID: 85029654790     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.08.020     Document Type: Review

References (122)

1. Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 3 (2016), e196–e204.
2. Andreoli, F., Barbosa, A.J., Parenti, M.D., Del Rio, A., Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr. Pharm. Des. 19 (2013), 578–613.
3. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K., Schapira, M., Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11 (2012), 384–400.
4. Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., Buggy, J.J., A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22 (2008), 1026–1034.
5. Basavapathruni, A., Jin, L., Daigle, S.R., Majer, C.R., Therkelsen, C.A., Wigle, T.J., Kuntz, K.W., Chesworth, R., Pollock, R.M., Scott, M.P., et al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem. Biol. Drug Des. 80 (2012), 971–980.
6. Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K., Taussig, D.C., Rezai, K., Roumier, C., Herait, P., et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 3 (2016), e186–195.
7. Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih Ie, M., Conejo-Garcia, J.R., et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21 (2015), 231–238.
8. Borkin, D., He, S., Miao, H., Kempinska, K., Pollock, J., Chase, J., Purohit, T., Malik, B., Zhao, T., Wang, J., et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27 (2015), 589–602.
9. Bowers, E.M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M.A., Crump, N.T., Hazzalin, C.A., Liszczak, G., Yuan, H., et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17 (2010), 471–482.
10. Bradner, J.E., Hnisz, D., Young, R.A., Transcriptional addiction in cancer. Cell 168 (2017), 629–643.
11. Calebiro, D., Grassi, E.S., Eszlinger, M., Ronchi, C.L., Godbole, A., Bathon, K., Guizzardi, F., de Filippis, T., Krohn, K., Jaeschke, H., et al. Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas. J. Clin. Invest. 126 (2016), 3383–3388.
12. Cao, F., Townsend, E.C., Karatas, H., Xu, J., Li, L., Lee, S., Liu, L., Chen, Y., Ouillette, P., Zhu, J., et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 53 (2014), 247–261.
13. Carvalho, S., Vitor, A.C., Sridhara, S.C., Martins, F.B., Raposo, A.C., Desterro, J.M., Ferreira, J., de Almeida, S.F., SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife, 3, 2014, e02482.
14. Chan-Penebre, E., Armstrong, K., Drew, A., Grassian, A.R., Feldman, I., Knutson, S.K., Kuplast-Barr, K., Roche, M., Campbell, J., Ho, P., et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: in vitro and in vivo preclinical models. Mol. Cancer Ther. 16 (2017), 850–860.
15. Chesi, M., Nardini, E., Lim, R.S., Smith, K.D., Kuehl, W.M., Bergsagel, P.L., The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92 (1998), 3025–3034.
16. Comet, I., Riising, E.M., Leblanc, B., Helin, K., Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat. Rev. Cancer 16 (2016), 803–810.
17. Copeland, R.A., Solomon, M.E., Richon, V.M., Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8 (2009), 724–732.
18. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P.A., Allain, C.J., Klaus, C.R., Raimondi, A., Scott, M.P., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122 (2013), 1017–1025.
19. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Majer, C.R., Sneeringer, C.J., Song, J., Johnston, L.D., Scott, M.P., Smith, J.J., Xiao, Y., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20 (2011), 53–65.
20. de Almeida, S.F., Grosso, A.R., Koch, F., Fenouil, R., Carvalho, S., Andrade, J., Levezinho, H., Gut, M., Eick, D., et al. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36. Nat. Struct. Mol. Biol. 18 (2011), 977–983.
21. Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M., Kastritis, E., Gilpatrick, T., Paranal, R.M., Qi, J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146 (2011), 904–917.
22. Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., Ozato, K., The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. USA 100 (2003), 8758–8763.
23. Dhar, S., Vemulapalli, V., Patananan, A.N., Huang, G.L., Di Lorenzo, A., Richard, S., Comb, M.J., Guo, A., Clarke, S.G., Bedford, M.T., Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs. Sci. Rep., 3, 2013, 1311.
24. Erdel, F., Rippe, K., Chromatin remodelling in mammalian cells by ISWI-type complexes—where, when and why?. FEBS J. 278 (2011), 3608–3618.
25. Farria, A., Li, W., Dent, S.Y., KATs in cancer: functions and therapies. Oncogene 34 (2015), 4901–4913.
26. Ferguson, A.D., Larsen, N.A., Howard, T., Pollard, H., Green, I., Grande, C., Cheung, T., Garcia-Arenas, R., Cowen, S., Wu, J., et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure 19 (2011), 1262–1273.
27. Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Muller, S., Pawson, T., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149 (2012), 214–231.
28. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse, E.M., Keates, T., Hickman, T.T., Felletar, I., et al. Selective inhibition of BET bromodomains. Nature 468 (2010), 1067–1073.
29. Finley, A., Copeland, R.A., Small molecule control of chromatin remodeling. Chem. Biol. 21 (2014), 1196–1210.
30. Finnin, M.S., Donigian, J.R., Cohen, A., Richon, V.M., Rifkind, R.A., Marks, P.A., Breslow, R., Pavletich, N.P., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999), 188–193.
31. French, C.A., Demystified molecular pathology of NUT midline carcinomas. J. Clin. Pathol. 63 (2010), 492–496.
32. Frumm, S.M., Fan, Z.P., Ross, K.N., Duvall, J.R., Gupta, S., VerPlank, L., Suh, B.C., Holson, E., Wagner, F.F., Smith, W.B., et al. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem. Biol. 20 (2013), 713–725.
33. Fuhrmann, J., Clancy, K.W., Thompson, P.R., Chemical biology of protein arginine modifications in epigenetic regulation. Chem. Rev. 115 (2015), 5413–5461.
34. Furumai, R., Matsuyama, A., Kobashi, N., Lee, K.H., Nishiyama, M., Nakajima, H., Tanaka, A., Komatsu, Y., Nishino, N., Yoshida, M., Horinouchi, S., FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62 (2002), 4916–4921.
35. Gerhold, C.B., Gasser, S.M., INO80 and SWR complexes: relating structure to function in chromatin remodeling. Trends Cell Biol. 24 (2014), 619–631.
36. Goldberg, A.D., Banaszynski, L.A., Noh, K.M., Lewis, P.W., Elsaesser, S.J., Stadler, S., Dewell, S., Law, M., Guo, X., Li, X., et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140 (2010), 678–691.
37. Grebien, F., Vedadi, M., Getlik, M., Giambruno, R., Grover, A., Avellino, R., Skucha, A., Vittori, S., Kuznetsova, E., Smil, D., et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPalpha N-terminal leukemia. Nat. Chem. Biol. 11 (2015), 571–578.
38. Green, M.R., Kihira, S., Liu, C.L., Nair, R.V., Salari, R., Gentles, A.J., Irish, J., Stehr, H., Vicente-Duenas, C., Romero-Camarero, I., et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. USA 112 (2015), E1116–E1125.
39. Gregoretti, I.V., Lee, Y.M., Goodson, H.V., Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338 (2004), 17–31.
40. Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A.G., Sorenson, R.J., Showalter, H.D., Murai, M.J., Belcher, A.M., Hartley, T., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8 (2012), 277–284.
41. Hammitzsch, A., Tallant, C., Fedorov, O., O'Mahony, A., Brennan, P.E., Hay, D.A., Martinez, F.O., Al-Mossawi, M.H., de Wit, J., Vecellio, M., et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc. Natl. Acad. Sci. USA 112 (2015), 10768–10773.
42. Haynes, S.R., Dollard, C., Winston, F., Beck, S., Trowsdale, J., Dawid, I.B., The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins. Nucleic Acids Res., 20, 1992, 2603.
43. He, Y., Selvaraju, S., Curtin, M.L., Jakob, C.G., Zhu, H., Comess, K.M., Shaw, B., The, J., Lima-Fernandes, E., Szewczyk, M.M., et al. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat. Chem. Biol. 13 (2017), 389–395.
44. Helming, K.C., Wang, X., Wilson, B.G., Vazquez, F., Haswell, J.R., Manchester, H.E., Kim, Y., Kryukov, G.V., Ghandi, M., Aguirre, A.J., et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat. Med. 20 (2014), 251–254.
45. Hodawadekar, S.C., Marmorstein, R., Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26 (2007), 5528–5540.
46. Hoffman, G.R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl. Acad. Sci. USA 111 (2014), 3128–3133.
47. Humphreys, P.G., Bamborough, P., Chung, C.W., Craggs, P.D., Gordon, L., Grandi, P., Hayhow, T.G., Hussain, J., Jones, K.L., Lindon, M., et al. Discovery of a potent, cell penetrant, and selective p300/CBP-associated factor (PCAF)/general control nonderepressible 5 (GCN5) bromodomain chemical probe. J. Med. Chem. 60 (2017), 695–709.
48. Italiano, A., Keilhack, H., Toulmonde, M., Coindre, J.M., Michot, J.M., Massard, C., Ottesen, L., Reyderman, L., Blakemore, S.J., Kraljevic, S., et al. A phase 1 study of EPZ-6438 (E7438), an enhancer of zeste-homolog 2 (EZH2) inhibitor: preliminary activity in INI1-negative tumors. Eur. J. Cancer 51 Suppl. 3 (2015), S54–S55.
49. Jaffe, J.D., Wang, Y., Chan, H.M., Zhang, J., Huether, R., Kryukov, G.V., Bhang, H.E., Taylor, J.E., Hu, M., Englund, N.P., et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45 (2013), 1386–1391.
50. James, L.I., Barsyte-Lovejoy, D., Zhong, N., Krichevsky, L., Korboukh, V.K., Herold, J.M., MacNevin, C.J., Norris, J.L., Sagum, C.A., Tempel, W., et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat. Chem. Biol. 9 (2013), 184–191.
51. James, L.I., Frye, S.V., Targeting chromatin readers. Clin. Pharmacol. Ther. 93 (2013), 312–314.
52. Juttermann, R., Li, E., Jaenisch, R., Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA 91 (1994), 11797–11801.
53. Kadoch, C., Copeland, R.A., Keilhack, H., PRC2 and SWI/SNF chromatin remodeling complexes in health and disease. Biochemistry 55 (2016), 1600–1614.
54. Kadoch, C., Crabtree, G.R., Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv., 1, 2015, e1500447.
55. Kaniskan, H.U., Szewczyk, M.M., Yu, Z., Eram, M.S., Yang, X., Schmidt, K., Luo, X., Dai, M., He, F., Zang, I., et al. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew. Chem. Int. Ed. 54 (2015), 5166–5170.
56. Killela, P.J., Reitman, Z.J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L.A. Jr., Friedman, A.H., Friedman, H., Gallia, G.L., Giovanella, B.C., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. USA 110 (2013), 6021–6026.
57. Kim, K.H., Kim, W., Howard, T.P., Vazquez, F., Tsherniak, A., Wu, J.N., Wang, W., Haswell, J.R., Walensky, L.D., Hahn, W.C., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21 (2015), 1491–1496.
58. Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Porter Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 110 (2013), 7922–7927.
59. Kooistra, S.M., Helin, K., Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 13 (2012), 297–311.
60. Koschmann, C., Calinescu, A.A., Nunez, F.J., Mackay, A., Fazal-Salom, J., Thomas, D., Mendez, F., Kamran, N., Dzaman, M., Mulpuri, L., et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci. Transl. Med., 8, 2016, 328ra28.
61. Kryukov, G.V., Wilson, F.H., Ruth, J.R., Paulk, J., Tsherniak, A., Marlow, S.E., Vazquez, F., Weir, B.A., Fitzgerald, M.E., Tanaka, M., et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351 (2016), 1214–1218.
62. Kuo, A.J., Cheung, P., Chen, K., Zee, B.M., Kioi, M., Lauring, J., Xi, Y., Park, B.H., Shi, X., Garcia, B.A., et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44 (2011), 609–620.
63. Kuo, A.J., Song, J., Cheung, P., Ishibe-Murakami, S., Yamazoe, S., Chen, J.K., Patel, D.J., Gozani, O., The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome. Nature 484 (2012), 115–119.
64. Lee, K.K., Workman, J.L., Histone acetyltransferase complexes: one size doesn't fit all. Nat. Rev. Mol. Cell Biol. 8 (2007), 284–295.
65. Legube, G., Trouche, D., Regulating histone acetyltransferases and deacetylases. EMBO Rep. 4 (2003), 944–947.
66. Lewis, H.D., Liddle, J., Coote, J.E., Atkinson, S.J., Barker, M.D., Bax, B.D., Bicker, K.L., Bingham, R.P., Campbell, M., Chen, Y.H., et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat. Chem. Biol. 11 (2015), 189–191.
67. Li, F., Mao, G., Tong, D., Huang, J., Gu, L., Yang, W., Li, G.M., The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 153 (2013), 590–600.
68. Li, W., Mills, A.A., Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes. Epigenomics 6 (2014), 381–395.
69. Liu, X., Wang, L., Zhao, K., Thompson, P.R., Hwang, Y., Marmorstein, R., Cole, P.A., The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451 (2008), 846–850.
70. Lombardi, P.M., Cole, K.E., Dowling, D.P., Christianson, D.W., Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr. Opin. Struct. Biol. 21 (2011), 735–743.
71. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., Pazdur, R., FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 (2007), 1247–1252.
72. Marjon, K., Cameron, M.J., Quang, P., Clasquin, M.F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 15 (2016), 574–587.
73. Mavrakis, K.J., McDonald, E.R. 3rd, Schlabach, M.R., Billy, E., Hoffman, G.R., deWeck, A., Ruddy, D.A., Venkatesan, K., Yu, J., McAllister, G., et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351 (2016), 1208–1213.
74. McAllister, T.E., England, K.S., Hopkinson, R.J., Brennan, P.E., Kawamura, A., Schofield, C.J., Recent progress in histone demethylase inhibitors. J. Med. Chem. 59 (2016), 1308–1329.
75. Meyer, C., Hofmann, J., Burmeister, T., Groger, D., Park, T.S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. The MLL recombinome of acute leukemias in 2013. Leukemia 27 (2013), 2165–2176.
76. Mirguet, O., Gosmini, R., Toum, J., Clement, C.A., Barnathan, M., Brusq, J.M., Mordaunt, J.E., Grimes, R.M., Crowe, M., Pineau, O., et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J. Med. Chem. 56 (2013), 7501–7515.
77. Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R., Paul, J.E., Boyle, M., Woolcock, B.W., Kuchenbauer, F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42 (2010), 181–185.
78. Moustakim, M., Clark, P.G., Trulli, L., Fuentes de Arriba, A.L., Ehebauer, M.T., Chaikuad, A., Murphy, E.J., Mendez-Johnson, J., Daniels, D., Hou, C.D., et al. Discovery of a PCAF bromodomain chemical probe. Angew. Chem. Int. Ed. 56 (2017), 827–831.
79. Mujtaba, S., Zeng, L., Zhou, M.M., Structure and acetyl-lysine recognition of the bromodomain. Oncogene 26 (2007), 5521–5527.
80. Nguyen, A.T., Zhang, Y., The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 25 (2011), 1345–1358.
81. Oike, T., Ogiwara, H., Tominaga, Y., Ito, K., Ando, O., Tsuta, K., Mizukami, T., Shimada, Y., Isomura, H., Komachi, M., et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 73 (2013), 5508–5518.
82. Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V.M., Su, L., Xu, G., Zhang, Y., hDOT1L links histone methylation to leukemogenesis. Cell 121 (2005), 167–178.
83. Okano, M., Xie, S., Li, E., Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19 (1998), 219–220.
84. Ortega-Molina, A., Boss, I.W., Canela, A., Pan, H., Jiang, Y., Zhao, C., Jiang, M., Hu, D., Agirre, X., Niesvizky, I., et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat. Med. 21 (2015), 1199–1208.
85. Owen, D.J., Ornaghi, P., Yang, J.C., Lowe, N., Evans, P.R., Ballario, P., Neuhaus, D., Filetici, P., Travers, A.A., The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 19 (2000), 6141–6149.
86. Pfister, S.X., Ashworth, A., Marked for death: targeting epigenetic changes in cancer. Nat. Rev. Drug Discov. 16 (2017), 241–263.
87. Picaud, S., Fedorov, O., Thanasopoulou, A., Leonards, K., Jones, K., Meier, J., Olzscha, H., Monteiro, O., Martin, S., Philpott, M., et al. Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Cancer Res. 75 (2015), 5106–5119.
88. Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. USA 110 (2013), 19754–19759.
89. Piunti, A., Shilatifard, A., Epigenetic balance of gene expression by Polycomb and COMPASS families. Science, 352, 2016, aad9780.
90. Prange, K.H., Mandoli, A., Kuznetsova, T., Wang, S.Y., Sotoca, A.M., Marneth, A.E., van der Reijden, B.A., Stunnenberg, H.G., Martens, J.H., MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Oncogene 36 (2017), 3346–3356.
91. Prince, H.M., Bishton, M.J., Harrison, S.J., Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 15 (2009), 3958–3969.
92. Ptashne, M., Epigenetics: core misconcept. Proc. Natl. Acad. Sci. USA 110 (2013), 7101–7103.
93. Qi, W., Zhao, K., Gu, J., Huang, Y., Wang, Y., Zhang, H., Zhang, M., Zhang, J., Yu, Z., Li, L., et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat. Chem. Biol. 13 (2017), 381–388.
94. Ramamoorthy, M., Smith, S., Loss of ATRX suppresses resolution of telomere cohesion to control recombination in ALT cancer cells. Cancer Cell 28 (2015), 357–369.
95. Redic, K.A., Hough, S.M., Price, E.M., Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. Onco Targets Ther. 9 (2016), 2783–2793.
96. Ribrag, V., Soria, J.C., Michot, J.M., Schmitt, A., Postel-Vinay, S., Bijou, F., Thomson, B., Keilhack, H., Blakemore, S.J., Reyderman, L., et al. A phase I study of tazemetostat (EPZ-6438), an inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): preliminary safety and activity in relapsed or refractory non-Hodgkin lymphoma (NHL) patients. Blood, 126, 2015, 473.
97. Richon, V.M., Johnston, D., Sneeringer, C.J., Jin, L., Majer, C.R., Elliston, K., Jerva, L.F., Scott, M.P., Copeland, R.A., Chemogenetic analysis of human protein methyltransferases. Chem. Biol. Drug Des. 78 (2011), 199–210.
98. Ronnekleiv-Kelly, S.M., Sharma, A., Ahuja, N., Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treat. Rev. 55 (2017), 200–208.
99. Santo, L., Hideshima, T., Kung, A.L., Tseng, J.C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J.H., Mazitschek, R., et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119 (2012), 2579–2589.
100. Shain, A.H., Pollack, J.R., The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One, 8, 2013, e55119.
101. Shilatifard, A., The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem. 81 (2012), 65–95.
102. Shortt, J., Ott, C.J., Johnstone, R.W., Bradner, J.E., A chemical probe toolbox for dissecting the cancer epigenome. Nat. Rev. Cancer 17 (2017), 160–183.
103. Simon, J.M., Hacker, K.E., Singh, D., Brannon, A.R., Parker, J.S., Weiser, M., Ho, T.H., Kuan, P.F., Jonasch, E., Furey, T.S., et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res. 24 (2014), 241–250.
104. Smith, Z.D., Meissner, A., DNA methylation: roles in mammalian development. Nat. Rev. Genet. 14 (2013), 204–220.
105. Sneeringer, C.J., Scott, M.P., Kuntz, K.W., Knutson, S.K., Pollock, R.M., Richon, V.M., Copeland, R.A., Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 107 (2010), 20980–20985.
106. Soshnev, A.A., Josefowicz, S.Z., Allis, C.D., Greater than the sum of parts: complexity of the dynamic epigenome. Mol. Cell 62 (2016), 681–694.
107. Stanton, B.Z., Hodges, C., Calarco, J.P., Braun, S.M., Ku, W.L., Kadoch, C., Zhao, K., Crabtree, G.R., Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. Nat. Genet. 49 (2017), 282–288.
108. Stathis, A., Zucca, E., Bekradda, M., Gomez-Roca, C., Delord, J.P., de La Motte Rouge, T., Uro-Coste, E., de Braud, F., Pelosi, G., French, C.A., Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 6 (2016), 492–500.
109. Stein, E.M., Garcia-Manero, G., Rizzieri, D.A., Tibes, R., Berdeja, J.G., Jongen-Lavrencic, M., Altman, J.K., Dohner, H., Thomson, B., Blakemore, S.J., et al. A phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in adults with relapsed or refractory leukemia: safety, clinical activity, exposure and target inhibition. Blood, 126, 2015, 2547.
110. Stelow, E., A review of NUT midline carcinoma. Head Neck Pathol. 5 (2011), 31–35.
111. Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., Rao, A., Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 (2009), 930–935.
112. Tang, L., Nogales, E., Ciferri, C., Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription. Prog. Biophys. Mol. Biol. 102 (2010), 122–128.
113. Tessarz, P., Kouzarides, T., Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15 (2014), 703–708.
114. Vangamudi, B., Paul, T.A., Shah, P.K., Kost-Alimova, M., Nottebaum, L., Shi, X., Zhan, Y., Leo, E., Mahadeshwar, H.S., Protopopov, A., et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res. 75 (2015), 3865–3878.
115. Vedadi, M., Barsyte-Lovejoy, D., Liu, F., Rival-Gervier, S., Allali-Hassani, A., Labrie, V., Wigle, T.J., Dimaggio, P.A., Wasney, G.A., Siarheyeva, A., et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 7 (2011), 566–574.
116. Wang, X., Lee, R.S., Alver, B.H., Haswell, J.R., Wang, S., Mieczkowski, J., Drier, Y., Gillespie, S.M., Archer, T.C., Wu, J.N., et al. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat. Genet. 49 (2017), 289–295.
117. Wigle, T.J., Copeland, R.A., Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. Curr. Opin. Chem. Biol. 17 (2013), 369–378.
118. Wilson, B.G., Helming, K.C., Wang, X., Kim, Y., Vazquez, F., Jagani, Z., Hahn, W.C., Roberts, C.W., Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol. Cell. Biol. 34 (2014), 1136–1144.
119. Wilson, B.G., Wang, X., Shen, X., McKenna, E.S., Lemieux, M.E., Cho, Y.J., Koellhoffer, E.C., Pomeroy, S.L., Orkin, S.H., Roberts, C.W., Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18 (2010), 316–328.
120. Zagni, C., Floresta, G., Monciino, G., Rescifina, A., The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat. Med. Res. Rev., 2017, 10.1002/med.21437.
121. Zhang, J., Dominguez-Sola, D., Hussein, S., Lee, J.E., Holmes, A.B., Bansal, M., Vlasevska, S., Mo, T., Tang, H., Basso, K., et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat. Med. 21 (2015), 1190–1198.
122. Zhang, T., Cooper, S., Brockdorff, N., The interplay of histone modifications - writers that read. EMBO Rep. 16 (2015), 1467–1481.